Title : Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

Pub. Date : 2002 Jul 1

PMID : 12089223






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus
2 PURPOSE: We discovered that breast cancer resistance protein (BCRP), a recently identified adenosine triphosphate-binding cassette drug transporter, substantially limits the oral bioavailability of topotecan in mdr1a/1b(-/-) P-glycoprotein (P-gp) knockout and wild-type mice. Topotecan ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus